Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.
Clinical trial NCT04572620 · UNKNOWN
Trial details
- NCT number
- NCT04572620
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2020-09-07
- Primary completion
- 2021-09-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.